Stock KRBP KIROMIC BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Market Closed - OTC Markets
Other stock markets
 02:19:19 2024-04-29 pm EDT 		5-day change 1st Jan Change
2.31 USD -25.00% Intraday chart for Kiromic BioPharma, Inc. -11.15% +165.52%
Apr. 24 Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients CI
Apr. 02 Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
BU
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
CI
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
BU
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
CI
EARLY EFFICACY RESULTS SHOW PRIMARY LUNG TUMOR STABILIZATION AND COMPLETE DISAPPEARANCE OF BRAIN METASTASES IN SECOND PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL
AQ
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
BU
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial
CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kiromic BioPharma : Corporate Presentation
PU
KIROMIC BIOPHARMA ADDS VIRGINIA ONCOLOGY ASSOCIATES, PC AS THE SECOND CLINICAL TRIAL SITE IN THE ONGOING PHASE 1 DELTACEL-01 TRIAL
AQ
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
BU
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
BU
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
AQ
RESULTS FROM FIRST PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL INDICATE TUMOR REDUCTION AT TWO MONTHS
AQ
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
BU
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
CI
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
BU
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRBP Stock
  4. News Kiromic BioPharma, Inc.